A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia

European Urology

Volumn 61, Issue 5, 2012, Pages 994-1003

  Gacci, Mauro ^a   Corona, Giovanni ^a,b   Salvi, Matteo ^a   Vignozzi, Linda ^a   McVary, Kevin T ^c   Kaplan, Steven A ^d   Roehrborn, Claus G ^e   Serni, Sergio ^a   Mirone, Vincenzo ^f   Carini, Marco ^a   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c NORTHWESTERN UNIVERSITY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Benign prostatic hyperplasia; BPH; ED; Erectile dysfunction; IIEF; IPSS; Lower urinary tract symptoms; LUTS; PDE5; PDE5 I; Prostate

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; GISADENAFIL; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; TAMSULOSIN; UDENAFIL; VARDENAFIL;

BACKACHE; BODY MASS; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; META ANALYSIS; MYALGIA; PRIAPISM; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINE FLOW RATE; UROFLOWMETRY;

ADRENERGIC ALPHA-ANTAGONISTS; CARBOLINES; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; LOWER URINARY TRACT SYMPTOMS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSTATIC HYPERPLASIA; PURINES; PYRIMIDINES; SULFONAMIDES; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 84859422428     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.02.033     Document Type: Review

References (43)

1. M. Gacci, G. Del Popolo, and A. Macchiarella Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study J Urol 178 2007 2040 2043
2. M. Gacci, I. Eardley, and F. Giuliano Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia Eur Urol 60 2011 809 825
3. K.E. Andersson, W.C. de Groat, and K.T. McVary Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action Neurourol Urodyn 30 2011 292 301
4. C. Zhao, S.H. Kim, and S.W. Lee Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia BJU Int 107 2011 1943 1947
5. S. Filippi, A. Morelli, and P. Sandner Characterization and functional role of androgen-dependent PDE5 activity in the bladder Endocrinology 148 2007 1019 1029
6. A. Morelli, A.K. Chavalmane, and S. Filippi Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signalling hyper-activation J Sex Med 6 2009 91 106
7. A. Morelli, S. Filippi, and P. Sandner Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats J Sex Med 6 2009 1594 1608
8. B. Fibbi, A. Morelli, and L. Vignozzi Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract J Sex Med 7 2010 59 69
9. M. Gacci, A. Ierardi, and A.D. Rose Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study J Sex Med 7 2010 234 243
10. A. Morelli, E. Sarchielli, and P. Comeglio Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats J Sex Med 8 2011 2746 2760
11. A. Morelli, S. Filippi, and P. Comeglio Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats J Sex Med 7 2010 107 120
12. K.T. McVary, A. Rademaker, G.L. Lloyd, and P. Gann Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia J Urol 174 2005 1327 1333 (Pubitemid 41318722)
13. D. Behr-Roussel, S. Oger, and S. Caisey Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats Eur Urol 59 2011 272 279
14. K. Sairam, E. Kulinskaya, T.A. McNicholas, G.B. Boustead, and D.C. Hanbury Sildenafil influences lower urinary tract symptoms BJU Int 90 2002 836 839 (Pubitemid 36693615)
15. J.P. Mulhall, P. Guhring, M. Parker, and C. Hopps Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction J Sex Med 3 2006 662 667
16. K.T. McVary, C.G. Roehrborn, and J.C. Kaminetsky Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia J Urol 177 2007 1401 1407 (Pubitemid 46435965)
17. L. Liu, S. Zheng, P. Han, and Q. Wei Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis Urology 77 2011 123 129
18. H.K. Laydner, P. Oliveira, and C.R. Oliveira Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review BJU Int 107 2011 1104 1109
19. K.F. Schulz, D.G. Altman, D. Moher CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials BMC Med 8 2010 18
20. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12 (Pubitemid 26120810)
21. K.T. McVary, W. Monnig, J.L. Camps Jr., J.M. Young, L.J. Tseng, and G. van den Ende Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 2007 1071 1077 (Pubitemid 46216352)
22. C.G. Stief, H. Porst, D. Neuser, M. Beneke, and E. Ulbrich A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 53 2008 1236 1244
23. C.G. Roehrborn, K.T. McVary, A. Elion-Mboussa, and L. Viktrup Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study J Urol 180 2008 1228 1234
24. H. Porst, K.T. McVary, and F. Montorsi Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia Eur Urol 56 2009 727 736 Corrigendum. Eur Urol 2011;59:1082
25. N.A. Tamimi, I. Mincik, S. Haughie, J. Lamb, A. Crossland, and P. Ellis A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia BJU Int 106 2010 674 680
26. H. Porst, E.D. Kim, A.R. Casabé for the LVHJ study team Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial Eur Urol 60 2011 1105 1113
27. S.A. Kaplan, R.R. Gonzalez, and A.E. Te Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction Eur Urol 51 2007 1717 1723 (Pubitemid 46634750)
28. A. Bechara, S. Romano, and A. Casabé Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH pilot study J Sex Med 5 2008 2170 2178
29. G. Liguori, C. Trombetta, and G. De Giorgi Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. preliminary report J Sex Med 6 2009 544 552
30. A. Tuncel, V. Nalcacioglu, K. Ener, Y. Aslan, O. Aydin, and A. Atan Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction World J Urol 28 2010 17 22
31. Gacci M, Vittori G, Tosi N, et al. A randomised, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0,4 mg versus tamsulosin 0,4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. In press.
32. J.L. Martínez-Salamanca, J. Carballido, and I. Eardley Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence Eur Urol 60 2011 527 535
33. H. Tinel, B. Stelte-Ludwig, J. Hütter, and P. Sandner Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms BJU Int 98 2006 1259 1263 (Pubitemid 44721238)
34. R. Dmochowski, C. Roehrborn, S. Klise, L. Xu, J. Kaminetsky, and S. Kraus Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial J Urol 183 2010 1092 1097
35. Clinical practice guidelines. Management of BPH (revised, 2010). American Urological Association Web site. http://www.auanet.org/content/clinical- practice-guidelines/clinical-guidelines.cfm?sub=bph.
36. Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the treatment of non-neurogenic male LUTS. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/12-Male-LUTS.pdf.
37. R.S. Kirby, C. Roehrborn, and P. Boyle Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial Urology 61 2003 119 126 (Pubitemid 36151726)
38. C.G. Roehrborn, P. Siami, J. Barkin CombAT Study Group The influence of baseline parameters on changes in International Prostate Symptom Score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study Eur Urol 55 2009 461 471
39. G. Corona, E. Mannucci, G. Forti, and M. Maggi Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases Int J Androl 32 2009 587 598
40. G. Corona, G. Rastrelli, A. Morelli, L. Vignozzi, E. Mannucci, and M. Maggi Hypogonadism and metabolic syndrome J Endocrinol Invest 34 2011 557 567
41. C.F. Donatucci, G.B. Brock, and E.R. Goldfischer Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study BJU Int 107 2011 1110 1116
42. G. Corona, M. Monami, and G. Rastrelli Testosterone and metabolic syndrome: a meta-analysis study J Sex Med 8 2011 272 283
43. L. Vignozzi, A. Morelli, and E. Sarchielli Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit J Endocrinol 212 2012 71 84